Multiplex locus specific amplification

• US 20080293589A1
• Filed: 05/27/2008
• Published: 11/27/2008
• Est. Priority Date: 05/24/2007
• Status: Abandoned Application

• Current Assignee: Affymetrix, Inc. (Thermo Fisher Scientific Incorporated)
• Original Assignee: Affymetrix, Inc. (Thermo Fisher Scientific Incorporated)
• Inventors: Shapero, Michael H.
• Application Number:
  US12/127,770
• Publication Number:
  US 20080293589A1
• Time in Patent Office: Days
• US Class Current: 506/9
• CPC Class Codes: C12Q 1/6855 Ligating adaptors
• CPC Class Codes: C12Q 2521/301 Endonuclease
• CPC Class Codes: C12Q 2521/501 Ligase
• CPC Class Codes: C12Q 2531/125 Rolling circle
• CPC Class Codes: C40B 30/04 by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
• CPC Class Codes: C40B 40/06 Libraries containing nucleotides or polynucleotides, or derivatives thereof

Abstract

Methods are provided for amplifying a plurality of pre-selected target sequences from a complex background of nucleic acids. The targets are selected for amplification using splint oligonucleotides that are used to modify the ends of the fragments. The fragments have known end sequences and the splints are designed to be complementary to the ends. In one aspect the splint brings the ends of the fragment together and the ends are joined to form a circle. In another aspect the splint is used to add a common priming site to the ends of the target fragments. Specific loci are amplified and can be subsequently analyzed.

Claims

1. A method for amplifying a plurality of target sequences from a nucleic acid sample and analyzing the amplified target sequences, said method comprising:

(a) fragmenting the nucleic acid sample with at least one restriction enzyme to generate fragments with known sequences at the 5′

fragment end and the 3′

fragment end, wherein at least some of the fragments are target fragments;

(b) mixing the fragments obtained in (a) with a plurality of target specific splint oligonucleotides, wherein each splint oligonucleotide comprises a first sequence that is at least 10 bases in length and is perfectly complementary to the at least 10 bases at the 5′

end of a corresponding target fragment, and a second sequence that is at least 10 bases in length and is perfectly complementary to the at least 10 bases at and including the 3′

end of said corresponding target fragment, and wherein said first sequence is 5′

of said second sequence in said splint oligonucleotide, wherein target specific splint oligonucleotides hybridize to corresponding target fragments so that the 5′ and

3′

ends of the hybridized target fragments are brought into proximity of one another;

(c) ligating the ends of the hybridized target fragments to obtain circularized target fragments;

(d) separating the circularized target fragments from splint oligonucleotides and uncircularized fragments;

(e) amplifying the circular target fragments to obtain amplified target sequences; and

(f) analyzing the amplified target sequences using an array comprising a plurality of oligonucleotide probes present at known or determinable locations in the array.

2. The method of claim 1, wherein prior to step (f) amplified target sequences are fragmented to obtain amplified target fragments and the amplified target fragments are labeled with a detectable label to obtain labeled fragments and wherein said step of analyzing comprises hybridizing the labeled fragments to said array.

3. The method of claim 1 wherein said plurality of target sequences comprises between 100 and 100,000 different target sequences.

4. The method of claim 1 wherein said plurality of target sequences comprises between 1,000,000 and 3,000,000 different target sequences.

5. The method of claim 1 wherein step (d) comprises digesting splint oligonucleotides and uncircularized fragments using an exonuclease.

6. The method of claim 1 wherein step (d) comprises hybridizing a plurality of target specific oligonucleotides to the circles, wherein said target specific oligonucleotides are biotinylated and separating the target circles from non-target sequence using streptavidin affinity matrix.

7. The method of claim 1 wherein said amplifying comprises incubation of the circular target fragments with random primers and a strand displacing DNA polymerase

8. The method of claim 1 wherein said step of analyzing is to determine the genotype of polymorphisms in said target sequences in said nucleic acid sample.

9. The method of claim 1 wherein said step of analyzing is to determine the methylation status of one or more cytosines in said target sequences in said nucleic acid smaple.

10. The method of claim 1 wherein said step of analyzing is to determine the presence or absence of specific target sequences in said nucleic acid sample.

11. The method of claim 1 wherein each of said target specific splint oligonucleotides comprises a different tag sequence between said first sequence and said second sequence and wherein the 3′

end of the target fragment is extended along the splint oligonucleotide using a DNA polymerase to incorporate the complement of the tag sequence into the fragment before ligating the ends to form a circular fragment comprising a tag sequence complement and wherein said array is an array of tag probes.

12. A method for amplifying and analyzing a plurality of target sequences from a nucleic acid sample, said method comprising:

(a) fragmenting the nucleic acid sample with a restriction enzyme to obtain fragments with known sequences at the 5′ and

3′

ends of the fragments, wherein said fragments comprise a plurality of target fragments comprising target sequences;

(b) mixing the fragments obtained in (a) with a plurality of target specific splint oligonucleotides, wherein each splint oligonucleotide comprises a first target complementary sequence that is at least 10 bases in length and is perfectly complementary to the at least 10 bases at the 3′

end of a corresponding target fragment, and a second target complementary sequence that is at least 10 bases in length and is perfectly complementary to the at least 10 bases at and including the 5′

end of said corresponding target fragment, and wherein said first sequence is 5′

of said second sequence in said splint oligonucleotide, wherein target specific splint oligonucleotides further comprises a first common priming sequence at the 5′

end and a second common priming sequence at the 3′

end;

(c) adding first and second primers to the mixture wherein said first primer is complementary to said first common priming sequence and said second primer is complementary to said second common priming sequence and wherein said first and second primers hybridize to said splint oligonucleotides so the first primer is adjacent to the 3′

end of the target fragment and the second primer is adjacent to the 5′

end of the target fragment;

(d) ligating the first primer to the 3′

end of the target fragment and the second primer to the 5′

end of the target fragment to obtain ligated target fragments comprising a first common priming site at the 3′

end and a second common priming sites at the 5′

end;

(e) after said ligating step (d) fragmenting said splint oligonucleotides;

(f) amplifying the ligated target fragments from (d) to obtain amplified target fragments; and

(g) analyzing the amplified target fragments by a method comprising hybridization to an array comprising a plurality of oligonucleotide probes present at known or determinable locations in the array.

14. The method of claim 12 wherein the second primer comprises a nicking position and wherein said amplifying comprises:

(a) making the ligated target fragments double stranded;

(b) nicking the nicking position;

(c) extending from the nick using a strand displacing DNA polymerase; and

(d) repeating steps (b) and (c).

21. The method of claim 12 wherein the splint oligonucleotides comprise one or more uracil bases and wherein the splint oligonucleotides are cleaved by uracil DNA glycosidase treatment, wherein the uracil is converted to an abasic site by uracil DNA glycosidase and the abasic sites are cleaved.

13. The method of claim 13 wherein each splint oligonucleotide further comprises a target fragment specific tag sequences located between the first target complementary sequence and the first common priming sequence or between the second target complementary sequence and the second common priming sequence and wherein tag complement oligonucleotides that are complementary to the tag sequences in the splint oligonucleotides are added at step (c) and ligated to the target fragments in step (d) so that the tag complements are adjacent to one of the common priming sequence in the ligated target fragments and wherein the array is a tag array.

15. The method of claim 13 wherein said nicking is by cleavage with a nicking restriction enzyme.

16. The method according to claim 13, wherein said second primer is between 15 and 50 bases in length.

17. The method of claim 13, wherein said DNA polymerase is active at a temperature between 30°

C. and 80°

C.

18. The method according to claim 13, wherein the DNA polymerase is Bst DNA polymerase and is active between 50°

C. to 65°

C.

19. The method according to claim 13, wherein said nicking is by Endo V.

20. The method of claim 19, wherein said Endo V is a thermal stable version.